share_log

Transcode Therapeutics | 8-K: Current report

Transcode Therapeutics | 8-K: Current report

Transcode Therapeutics | 8-K：重大事件
美股sec公告 ·  06/14 05:09
牛牛AI助理已提取核心訊息
TransCode Therapeutics, Inc. held its 2024 Annual Meeting of Stockholders on June 13, 2024, where several key proposals were voted upon. The meeting saw the election of four directors, Philippe P. Calais, PhD, Thomas A. Fitzgerald, Erik Manting, PhD, and Magda Marquet, PhD, each for a one-year term. Additionally, stockholders approved an amendment to increase the number of shares available under the company's 2021 Stock Option and Incentive Plan by 3,000,000 shares. The appointment of WithumSmith+Brown, PC as the independent registered public accounting firm for the fiscal year ending December 31, 2024, was ratified. However, the proposal for a reverse stock split of common stock by a ratio between 1-for-2 and 1-for-40 was not approved. An adjournment proposal was passed in case there were insufficient votes to approve the reverse stock split or the stock plan amendment, but it was not needed as the latter was approved. The total number of shares entitled to vote was 6,108,053, with 2,392,577 shares present or represented by proxy.
TransCode Therapeutics, Inc. held its 2024 Annual Meeting of Stockholders on June 13, 2024, where several key proposals were voted upon. The meeting saw the election of four directors, Philippe P. Calais, PhD, Thomas A. Fitzgerald, Erik Manting, PhD, and Magda Marquet, PhD, each for a one-year term. Additionally, stockholders approved an amendment to increase the number of shares available under the company's 2021 Stock Option and Incentive Plan by 3,000,000 shares. The appointment of WithumSmith+Brown, PC as the independent registered public accounting firm for the fiscal year ending December 31, 2024, was ratified. However, the proposal for a reverse stock split of common stock by a ratio between 1-for-2 and 1-for-40 was not approved. An adjournment proposal was passed in case there were insufficient votes to approve the reverse stock split or the stock plan amendment, but it was not needed as the latter was approved. The total number of shares entitled to vote was 6,108,053, with 2,392,577 shares present or represented by proxy.
TransCode Therapeutics，Inc於2024年6月13日舉行了2024年股東年會，關於幾個關鍵提案進行了表決。選舉產生了四名董事：Philippe P. Calais博士、Thomas A.Fitzgerald、Erik Manting博士和Magda Marquet博士，任期爲一年。此外，股東通過了一項修正案，通過增加公司2021年股票期權和激勵計劃下可用股票數量300萬股。任命WithumSmith+Brown、PC爲獨立註冊公共會計事務所，審計截止日期爲2024年12月31日。然而，針對普通股的1：2至1：40的反向股票分割提案未獲得通過。爲了防止反向股票分割或股票計劃修訂未獲得批准的投票不足，提出了休會的提案，但由於後者已獲得批准，因此不需要這個提案。股東獲得投票權的股份總數爲6,108,053股，其中有2,392,577股出席或代表。
TransCode Therapeutics，Inc於2024年6月13日舉行了2024年股東年會，關於幾個關鍵提案進行了表決。選舉產生了四名董事：Philippe P. Calais博士、Thomas A.Fitzgerald、Erik Manting博士和Magda Marquet博士，任期爲一年。此外，股東通過了一項修正案，通過增加公司2021年股票期權和激勵計劃下可用股票數量300萬股。任命WithumSmith+Brown、PC爲獨立註冊公共會計事務所，審計截止日期爲2024年12月31日。然而，針對普通股的1：2至1：40的反向股票分割提案未獲得通過。爲了防止反向股票分割或股票計劃修訂未獲得批准的投票不足，提出了休會的提案，但由於後者已獲得批准，因此不需要這個提案。股東獲得投票權的股份總數爲6,108,053股，其中有2,392,577股出席或代表。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。